Mark Elliott Boulding - Apr 13, 2022 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
EXEC. VP AND CLO
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Apr 13, 2022
Transactions value $
-$102,811
Form type
4
Date filed
4/15/2022, 04:02 PM
Previous filing
Apr 7, 2022
Next filing
Sep 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $25.6K +2.28K +3.72% $11.23 63.4K Apr 13, 2022 Direct F1
transaction PTCT Common Stock Sale -$103K -2.28K -3.59% $45.17 61.1K Apr 13, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise -$25.6K -2.28K -100% $11.23 0 Apr 13, 2022 Common Stock 2.28K $11.23 Direct F1, F3
holding PTCT Stock Option (Right to Buy) 85.6K Apr 13, 2022 Common Stock 85.6K $51.00 Direct F3
holding PTCT Stock Option (Right to Buy) 70K Apr 13, 2022 Common Stock 70K $30.86 Direct F3
holding PTCT Stock Option (Right to Buy) 72.5K Apr 13, 2022 Common Stock 72.5K $33.02 Direct F4
holding PTCT Stock Option (Right to Buy) 17.5K Apr 13, 2022 Common Stock 17.5K $33.02 Direct F5
holding PTCT Stock Option (Right to Buy) 59.5K Apr 13, 2022 Common Stock 59.5K $51.16 Direct F6
holding PTCT Stock Option (Right to Buy) 59.5K Apr 13, 2022 Common Stock 59.5K $66.49 Direct F7
holding PTCT Stock Option (Right to Buy) 54K Apr 13, 2022 Common Stock 54K $38.10 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021.
F2 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.35 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Currently exercisable.
F4 This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F5 This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F6 This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F7 This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
F8 This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.